Virax Biolabs Group Limited (VRAX)
NASDAQ: VRAX · Real-Time Price · USD
0.1041
-0.0308 (-22.83%)
At close: Apr 10, 2026, 4:00 PM EDT
0.1750
+0.0709 (68.11%)
After-hours: Apr 10, 2026, 7:59 PM EDT
Virax Biolabs Group Employees
Virax Biolabs Group had 19 employees as of March 31, 2025. The number of employees increased by 2 or 11.76% compared to the previous year.
Employees
19
Change (1Y)
2
Growth (1Y)
11.76%
Revenue / Employee
$157
Profits / Employee
-$297,031
Market Cap
772.78K
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Mar 31, 2025 | 19 | 2 | 11.76% |
| Mar 31, 2024 | 17 | 6 | 54.55% |
| Mar 31, 2023 | 11 | 6 | 120.00% |
| Mar 31, 2022 | 5 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| HCW Biologics | 36 |
| Scinai Immunotherapeutics | 31 |
| Aditxt | 26 |
| Biodexa Pharmaceuticals | 11 |
| CDT Equity | 6 |
| CNS Pharmaceuticals | 5 |
| Adial Pharmaceuticals | 5 |
| Onconetix | 2 |
VRAX News
- 10 days ago - What's Behind The Jump In Virax Biolabs Stock? - Benzinga
- 10 days ago - Virax Biolabs Achieves ISO Certifications, Laying Foundation for Regulated IVD Development and U.S. Clinical Validation - PRNewsWire
- 4 months ago - Virax Biolabs Group Limited Announces Closing of $5 Million Private Placement - PRNewsWire
- 4 months ago - Virax Biolabs Group Limited Announces $5 Million Private Placement - PRNewsWire
- 4 months ago - Virax Biolabs' CEO James Foster Outlines Clinical Progress and 2026 Priorities in Latest Annual Letter to Shareholders - PRNewsWire
- 5 months ago - Virax Biolabs Completes UK Clinical Recruitment and Reports Constructive FDA Feedback for ViraxImmune™ Study Evaluating T Cell Dysfunction in Post-Acute Infection Syndromes - PRNewsWire
- 8 months ago - Virax Biolabs Partners with Emory University on ViraxImmune™ Clinical Studies; Readies for FDA Pre-Submission Meeting in Early September - PRNewsWire
- 9 months ago - Virax Biolabs Appoints Iain Miller, PhD as Independent Director to Accelerate Commercial Strategy - PRNewsWire